Login | Create Account (DAF staff only)

Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model

Bernigaud, C. and Fang, F. and Fischer, K. and Lespine, A. and Aho, L. S. and Dreau, D. and Kelly, A. and Sutra, J. F. and Moreau, F. and Lilin, T. and Botterel, F. and Guillot, J. and Chosidow, O. (2016) Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model. PLoS Neglected Tropical Diseases, 10 (10).

Full text not currently attached. Access may be available via the Publisher's website or OpenAccess link.

Article Link(s): http://dx.doi.org/10.1371/journal.pntd.0005030

Publisher URL: http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005030&type=printable

Abstract

Background: Scabies is one of the commonest dermatological conditions globally; however it is a largely underexplored and truly neglected infectious disease. Foremost, improvement in the management of this public health burden is imperative. Current treatments with topical agents and/or oral ivermectin (IVM) are insufficient and drug resistance is emerging. Moxidectin (MOX), with more advantageous pharmacological profiles may be a promising alternative. Methodology/Principal Findings: Using a porcine scabies model, 12 pigs were randomly assigned to receive orally either MOX (0.3 mg/kg once), IVM (0.2 mg/kg twice) or no treatment. We evaluated treatment efficacies by assessing mite count, clinical lesions, pruritus and ELISA-determined anti-S. scabiei IgG antibodies reductions. Plasma and skin pharmacokinetic profiles were determined. At day 14 post-treatment, all four MOX-treated but only two IVM-treated pigs were mite-free. MOX efficacy was 100% and remained unchanged until study-end (D47), compared to 62% (range 26–100%) for IVM, with one IVM-treated pig remaining infected until D47. Clinical scabies lesions, pruritus and anti-S. scabiei IgG antibodies had completely disappeared in all MOX-treated but only 75% of IVM-treated pigs. MOX persisted ~9 times longer than IVM in plasma and skin, thereby covering the mite’s entire life cycle and enabling long-lasting efficacy. Conclusions/Significance: Our data demonstrate that oral single-dose MOX was more effective than two consecutive IVM-doses, supporting MOX as potential therapeutic approach for scabies. © 2016 Bernigaud et al.

Item Type:Article
Business groups:Animal Science
Subjects:Animal culture > Swine
Veterinary medicine > Communicable diseases of animals (General)
Deposited On:16 Jan 2017 23:19
Last Modified:16 Jan 2017 23:19

Repository Staff Only: item control page